News | Treatment Planning | September 23, 2019

Patients treated at Princess Margaret Cancer Centre in Toronto, Canada, as part of comprehensive evaluation study

First Patients Treated With Machine Learning-generated Plans from RayStation 8B

September 23, 2019 — The first-ever patient radiation therapy treatments generated with machine learning in the RayStation treatment planning system (TPS) have been conducted. Patients with localized prostate cancer are being treated with the technology at the Princess Margaret Cancer Centre in Toronto, Canada, as part of a comprehensive evaluation study.

RaySearch released the machine learning features in RayStation 8B in late December 2018. This technology has been developed by RaySearch’s in-house machine learning department in collaboration with researchers at the Princess Margaret Cancer Centre and Techna Institute, crystalizing years of cutting-edge research led by medical physicist Tom Purdie, Ph.D., and computer scientist Chris McIntosh, Ph.D. The features represent the first applications of machine learning in a TPS on the radiation oncology market, according to RaySearch, producing high-quality radiation treatment plans in only minutes, without the need for any user intervention.

Since May 2019, every patient with localized prostate cancer treated at the Princess Margaret has been part of a prospective initiative under the direction of radiation oncologist Alejandro Berlin, M.D. The initiative was launched after observing excellent clinical results in a retrospective evaluation study conducted during 2018, in which machine learning plans were preferred or deemed equivalent to previous manual plans based on three blinded expert reviewers in 94 percent of cases.

The ongoing phase of this study presents physicians with two blinded treatment plans: a manually generated plan and a machine learning plan. The selected plan undergoes standard peer-review and quality assurance, and then patients proceed to treatment delivery with the preferred plan.

This worldwide endeavor will provide unique data to quantify the performance and preferability of machine learning plans in the real-world environment.

Berlin said, “It has been really exciting for the team to help materialize this machine learning advancement in the radiation oncology field, including deployment into the clinical realm. Our positive results to date validate our observations about the robustness of this planning solution”.

For more information: www.raysearchlabs.com


Related Content

News | ASTRO

May 17, 2024 — Registration opens today for the American Society for Radiation Oncology's (ASTRO) 66th Annual Meeting ...

Time May 17, 2024
arrow
News | Radiation Therapy

May 16, 2024 — Today marks a significant milestone in cancer care with the introduction of bipartisan federal ...

Time May 16, 2024
arrow
Sponsored Content | Case Study | Enterprise Imaging

Having the most efficient clinical workflows with enhanced diagnostic capabilities is a major goal for clinicians and ...

Time May 16, 2024
arrow
News | FDA

May 14, 2024 — Indica Labs, the leading provider of digital pathology solutions, announced today that it received FDA ...

Time May 14, 2024
arrow
News | Radiology Business

May 14, 2024 — University Hospitals (UH) and Siemens Healthineers announce a 10-year strategic alliance that builds on ...

Time May 14, 2024
arrow
News | Artificial Intelligence

May 14, 2024 — Elekta announced the launch of its latest linear accelerator (linac), Evo*, a CT-Linac with new high ...

Time May 14, 2024
arrow
News | Prostate Cancer

May 13, 2024 — Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, unveils ...

Time May 13, 2024
arrow
News | Radiation Oncology

May 10, 2024 — Mariana Oncology, a fully integrated biotechnology company pioneering a new era of radiopharmaceutical ...

Time May 10, 2024
arrow
News | Radiation Oncology

May 10, 2024 — Insurance expansions under the Affordable Care Act (ACA) were linked with an increase in patients ...

Time May 10, 2024
arrow
News | Radiopharmaceuticals and Tracers

May 8, 2024 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of ...

Time May 08, 2024
arrow
Subscribe Now